Asia-Pacific preventive inhaler market is anticipated to grow at a substantial growth rate of around 3.8% during the forecast period. Major factors that augments the growth of the market include large population base susceptible to asthma and COPD, rising awareness about treatment for asthma and COPD, and significant presence of market players in the region. Asia-Pacific has a potential market due to the increasing R&D and investments by big pharmaceutical companies in life science research coupled with harnessing innovation. The preventive inhaler market in the Asia-Pacific region presents future opportunities for growth as the prevalence of respiratory diseases such as asthma, COPD in emerging economies such as India and China. In addition, increasing the geriatric population specially in Japan is another major reason for the growing market for preventive inhalers.

The Asia-Pacific preventive inhaler market is segmented on the basis of device type, application, and end-user. On the basis of device type, the market is sub-segmented into the metered dosed inhaler and dry powdered inhaler. The dry powder inhaler is estimated to have the largest market share in the Asia-Pacific preventive inhaler market due to providing an easy inhalation solution. Moreover, on the basis of application, the market has been classified into asthma and COPD diseases. In addition, based on the end-user, homecare and hospitals and clinics have been analyzed. 

Furthermore, the market is characterized by the presence of several manufacturers that are developing and providing preventive inhalers to cater to a wide range of customers within the region and across the globe. The major players of the Asia-Pacific preventive inhaler market include 3M Co., AstraZeneca PLC, Aradigm Corp., Adherium Ltd., GlaxoSmithKline PLC, Novartis AG, Propeller Health, Teva Pharmaceuticals Industries Ltd. These players adopt various strategies to capitalize on market growth opportunities. Mergers and acquisitions, product launch, geographical expansion, partnerships, and collaborations are the majorly adopted strategies by the market players. For instance, in May 2018, the company established a partnership with MannKind for marketing and distributing Afrezza. It is the only US FDA approved inhaled insulin available for patients suffering from diabetes. In addition, the company in February 2018, has entered into a partnership with Roche Pharma India for healthcare improvement and increasing access to life-changing medicines in India. 

Research Methodology

The market study of the Asia-Pacific preventive inhaler market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity of our reports.

Secondary Sources Include:

• Financial reports of companies involved in the market
• Whitepapers, research-papers, and news blogs
• Company websites and their product catalog

The report is intended for inhaler manufacturers, contract research organizations (CROs), healthcare sector, market research firms, and government organizations, for overall market analysis and competitive analysis. The report provides an in-depth analysis of the market size and growth opportunities. The report will serve as a source for 360-degree analysis of the market thoroughly delivering insights into the market for making better business decisions.

Market Segmentation:

1. Asia-Pacific Preventive Inhaler Market Research and Analysis by Device Type

2. Asia-Pacific Preventive Inhaler Market Research and Analysis by Application

3. Asia-Pacific Preventive Inhaler Market Research and Analysis by End-User

The Report covers:

• Comprehensive research methodology of the Asia-Pacific preventive inhaler market.
• This report also includes a detailed and extensive market overview with key analyst insights.
• An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
• Analysis of regional regulations and other government policies impacting the Asia-Pacific preventive inhaler market.
• Insights about market determinants which are stimulating the Asia-Pacific preventive inhaler market.
• Detailed and extensive market segments with regional distribution of forecasted revenues.
• Extensive profiles and recent developments of market players.